Zucara Therapeutics is in the process of developing the initial daily remedy to prevent low blood sugar (hypoglycemia) in individuals with diabetes. This preclinical innovation is focused on regulating a hormone known as somatostatin in the pancreas, which is not properly controlled in Type 1 diabetes. It has shown potential to specifically inhibit somatostatin type 2 receptors in the pancreas, thus averting hypoglycemia and reinstating natural blood glucose levels.